智通财经APP获悉，乐普生物(02157)涨近4%，早盘曾涨逾12%。截至发稿，涨3.83%，报4.61港元，成交额9164.84万港元。
消息面上，7月28日，乐普生物发布公告，有关集团与AstraZeneca AB(AstraZeneca，一家全球生物制药公司)就抗体偶联药物(ADC)候选药物CMG901(sonesitatug vedotin，亦称为AZD0901)合作的最新情况。据悉，于2023年2月，KYM Biosciences Inc.(KYM，一家由公司与康诺亚生物医药科技有限公司(康诺亚)成立的合营企业)与AstraZeneca已订立全球独家许可协议，以开发及商业化CMG901(公司与康诺亚通过KYM共同开发的候选药物)。
截至本公告日期，CLARITY-Gastric01全球III期临床试验公布的积极顶线结果显示，与研究者选择的治疗方案相比，sonesitatug vedotin在二线及后线(2L+) Claudin 18.2阳性晚期胃癌患者中展现出具有统计学显著性且极具临床意义的总生存期(OS)改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.